Literature DB >> 23152566

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Brian M Olson1, Ewa Jankowska-Gan, Jordan T Becker, Dario A A Vignali, William J Burlingham, Douglas G McNeel.   

Abstract

Regulatory T cells play important roles in cancer development and progression by limiting the generation of innate and adaptive anti-tumor immunity. We hypothesized that in addition to natural CD4(+)CD25(+) regulatory T cells (Tregs) and myeloid-derived suppressor cells, tumor Ag-specific Tregs interfere with the detection of anti-tumor immunity after immunotherapy. Using samples from prostate cancer patients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found that the detection of PAP-specific effector responses after immunization was prevented by the activity of PAP-specific regulatory cells. These regulatory cells were CD8(+)CTLA-4(+), and their suppression was relieved by blockade of CTLA-4, but not IL-10 or TGF-β. Moreover, Ag-specific CD8(+) Tregs were detected prior to immunization in the absence of PAP-specific effector responses. These PAP-specific CD8(+)CTLA-4(+) suppressor T cells expressed IL-35, which was decreased after blockade of CTLA-4, and inhibition of either CTLA-4 or IL-35 reversed PAP-specific suppression of tvDTH response. PAP-specific CD8(+)CTLA-4(+) T cells also suppressed T cell proliferation in an IL-35-dependent, contact-independent fashion. Taken together, these findings suggest a novel population of CD8(+)CTLA-4(+) IL-35-secreting tumor Ag-specific Tregs arise spontaneously in some prostate cancer patients, persist during immunization, and can prevent the detection of Ag-specific effector responses by an IL-35-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152566      PMCID: PMC3735346          DOI: 10.4049/jimmunol.1201744

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression.

Authors:  Z X Zhang; L Yang; K J Young; B DuTemple; L Zhang
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance.

Authors:  Vandana Chaturvedi; Lauren W Collison; Clifford S Guy; Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

3.  Antigen-specific TGF-β-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity.

Authors:  Thanh-Long M Nguyen; Nicole L Sullivan; Mark Ebel; Ryan M Teague; Richard J DiPaolo
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

4.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Authors:  A A Hurwitz; B A Foster; E D Kwon; T Truong; E M Choi; N M Greenberg; M B Burg; J P Allison
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

5.  Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

Authors:  Carlo Sorrentino; Piero Musiani; Paolo Pompa; Giuseppe Cipollone; Emma Di Carlo
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  Human allograft acceptance is associated with immune regulation.

Authors:  A M VanBuskirk; W J Burlingham; E Jankowska-Gan; T Chin; S Kusaka; F Geissler; R P Pelletier; C G Orosz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

7.  Functional plasticity of antigen-specific regulatory T cells in context of tumor.

Authors:  Caroline Addey; Matthew White; Lang Dou; David Coe; Julian Dyson; Jian-Guo Chai
Journal:  J Immunol       Date:  2011-03-09       Impact factor: 5.422

8.  IL-35-mediated induction of a potent regulatory T cell population.

Authors:  Lauren W Collison; Vandana Chaturvedi; Abigail L Henderson; Paul R Giacomin; Cliff Guy; Jaishree Bankoti; David Finkelstein; Karen Forbes; Creg J Workman; Scott A Brown; Jerold E Rehg; Michael L Jones; Hsiao-Tzu Ni; David Artis; Mary Jo Turk; Dario A A Vignali
Journal:  Nat Immunol       Date:  2010-10-17       Impact factor: 25.606

9.  Human liver allograft acceptance and the "tolerance assay". II. Donor HLA-A, -B but not DR antigens are able to trigger regulation of DTH.

Authors:  Ewa Jankowska-Gan; Tonja Rhein; Lynn D Haynes; Felix Geissler; Arend Mulder; Munci Kalayoglu; Hans Sollinger; William J Burlingham
Journal:  Hum Immunol       Date:  2002-10       Impact factor: 2.850

Review 10.  Type 1 T regulatory cells.

Authors:  M G Roncarolo; R Bacchetta; C Bordignon; S Narula; M K Levings
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

View more
  51 in total

Review 1.  Interleukin-35: Expanding Its Job Profile.

Authors:  Deepali V Sawant; Kristia Hamilton; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2015-04-28       Impact factor: 2.607

Review 2.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

Review 3.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

4.  Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.

Authors:  Bin Kong; Gan-Bin Liu; Jun-Ai Zhang; Xiao-Xia Fu; Wen-Yu Xiang; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Feng Qiu; Wan-Dang Wang; Lai-Long Yi; Ji-Xin Zhong; Zheng W Chen; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.

Authors:  Brian T Rekoske; Brian M Olson; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 8.110

Review 6.  Role of exosomes in tumour and transplant immune regulation.

Authors:  Diego A Lema; William J Burlingham
Journal:  Scand J Immunol       Date:  2019-07-31       Impact factor: 3.487

7.  Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.

Authors:  Jianwei Liu; Junli Wang; Weiping Jiang; Yujin Tang
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

8.  Assessing the role of IL-35 in colorectal cancer progression and prognosis.

Authors:  Jin-Cheng Zeng; Zhi Zhang; Tian-Yu Li; Yan-Fang Liang; Hong-Mei Wang; Jing-Jing Bao; Jun-Ai Zhang; Wan-Dang Wang; Wen-Yu Xiang; Bin Kong; Zhi-Yong Wang; Bin-Hua Wu; Xiao-Dong Chen; Long He; Shu Zhang; Cong-Yi Wang; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

9.  Interleukin (IL)-35 Suppresses IL-6 and IL-8 Production in IL-17A-Stimulated Human Periodontal Ligament Cells.

Authors:  Satoru Shindo; Yoshitaka Hosokawa; Ikuko Hosokawa; Hideki Shiba
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

10.  Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma.

Authors:  Lingwei Jin; Xiaoyan Xu; Bairu Ye; Min Pan; Zhen Shi; Yunling Hu
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.